App-Quantinova.ai

NEURO-COVID: DOES SEVERE COVID-19 INFECTION INCREASE THE RISK FOR COGNITIVE IMPAIRMENT?

Göran Hagman - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Parkinson's disease

N/A

A graph theory approach to detect age and Alzheimer’s disease related changes to structural neural networks.

Laura M Wright - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Mild cognitive impairment

N/A

A role for astrocytes and microglia in synapse loss in Alzheimer’s disease

Tara L Spires-Jones - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Obstetrics/Gynecology

Alzheimer's disease

N/A

Impact of reduced injected dose on the quantification of [18F]RO948 and [18F]Flortaucipir PET for in vivo tau pathology

Peter Young - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

The effect of a mindfulness-based versus health self-management intervention on cognitive performance in older adults with subjective cognitive decline (SCD): The SCD-Well randomized controlled trial

Tim Whitfield - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Alzheimer's disease

N/A

Beyond WMH volume: coalescence score as a new measure of cerebral small vessel disease pattern.

Carole H Sudre - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Cerebral small vessel disease

N/A

Do CSF synaptic and neuronal markers correlate with cognition in ageing and dementia? A systematic review

Tyler S Saunders - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Dementia

N/A

Gait characteristics in preclinical Alzheimer’s disease: preliminary results of the RADAR-AD study

Casper de Boer - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Alzheimer's disease

N/A

Speech-in-noise perception is a marker of preclinical Alzheimer’s disease

Sheena Waters - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Alzheimer's disease

N/A

Machine learning based neuropathology for dementia

Emmanuel Aapapa Jammeh - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Dementia

N/A

A network-based drug-screening platform for Alzheimer’s disease by integrating mathematical modeling and pathological features of human brain organoids

Jong-Chan Park - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Alzheimer's disease

N/A

Impact of clinical symptoms and diagnosis: The electronic Person-Specific Outcome Measure (ePSOM) development programme

Stina Saunders - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Mild cognitive impairment

N/A

Heparan sulfate: in vitro and in vivo proof of efficacy of this new therapeutic strategy for halting Alzheimer disease related tauopathies development

Gael Le Douaron - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Alzheimer's disease

N/A

An investigation into the association between diet and dementia risk

Ivelina Dobreva - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Dementia

N/A

A proposition for analyses and reporting standards for structural and functional magnetic resonance imaging of the noradrenergic Locus Coeruleus

Yeo-Jin Yi - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

Associations Between Mean Apparent Propagator MRI and Cerebrospinal Fluid Markers of AD Pathology, Neurodegeneration, and Glial Activation, in Cognitively Unimpaired Adults

Jason F Moody - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Alzheimer's disease

N/A

Baseline MRI and CSF Measurements in Cognitively-Normal Individuals as Prognostic Markers of Progression to Mild Cognitive Impairment

Lloyd Prosser - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

White matter hyperintensities

N/A

Brain amyloid load and cognitive trajectories in older individuals at risk for dementia

Gazi Saadmaan Hossain - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Dementia

N/A

Brain structural alterations in cognitively unimpaired individuals with discordant amyloid-β PET and CSF Aβ42 status: findings using Machine Learning

Irene Cumplido-Mayoral - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

Current Status and Quantitative Results of the AMYPAD Prognostic and Natural History Study

Juan Domingo Gispert - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

Filters

45280 Abstracts